Zacks Research Issues Pessimistic Outlook for EW Earnings

Edwards Lifesciences Co. (NYSE:EWFree Report) – Equities research analysts at Zacks Research cut their Q1 2025 earnings per share estimates for shares of Edwards Lifesciences in a research note issued on Thursday, November 14th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $0.59 for the quarter, down from their prior forecast of $0.69. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.57 per share. Zacks Research also issued estimates for Edwards Lifesciences’ Q2 2025 earnings at $0.62 EPS, Q3 2025 earnings at $0.59 EPS, Q4 2025 earnings at $0.64 EPS, Q1 2026 earnings at $0.67 EPS, Q2 2026 earnings at $0.70 EPS and Q3 2026 earnings at $0.71 EPS.

Edwards Lifesciences (NYSE:EWGet Free Report) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the previous year, the business earned $0.59 earnings per share. The business’s revenue was up 8.9% compared to the same quarter last year.

A number of other analysts have also recently commented on EW. Robert W. Baird cut their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Morgan Stanley reissued an “equal weight” rating and set a $70.00 target price on shares of Edwards Lifesciences in a report on Friday, October 11th. Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Jefferies Financial Group downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their price objective for the company from $85.00 to $70.00 in a research note on Wednesday, September 18th. Finally, Bank of America cut shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $105.00 to $75.00 in a research note on Thursday, July 25th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and an average price target of $75.67.

Read Our Latest Report on Edwards Lifesciences

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $69.89 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market cap of $41.22 billion, a PE ratio of 10.09, a PEG ratio of 3.81 and a beta of 1.12. Edwards Lifesciences has a one year low of $58.93 and a one year high of $96.12. The firm has a fifty day moving average of $67.53 and a 200 day moving average of $76.02.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,262,521.36. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 40,000 shares of company stock valued at $2,657,000 over the last 90 days. 1.29% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in EW. Crewe Advisors LLC acquired a new position in shares of Edwards Lifesciences in the first quarter worth $28,000. First Community Trust NA purchased a new position in Edwards Lifesciences in the second quarter valued at $29,000. FSA Wealth Management LLC acquired a new position in Edwards Lifesciences during the 3rd quarter worth $30,000. Prospera Private Wealth LLC purchased a new stake in Edwards Lifesciences during the 3rd quarter worth about $32,000. Finally, Avior Wealth Management LLC raised its position in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

(Get Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

See Also

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.